Drug Trial Radar · NCT07223047
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
Last checked: Nov 19, 2026Latest source record: May 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
252
Planned (sponsor's estimate)
Start
Nov 25, 2025
Primary completion
Oct 13, 2028
Study completion Oct 13, 2028
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Oct 31, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, tolerability, and efficacy of BMS-986523 alone and in combination with anti-cancer agents in participants with advanced solid malignancies
Conditions
- Advanced Solid Malignancies
- Non-small Cell Lung Cancer (NSCLC)
- Colorectal Cancer (CRC)
- Pancreatic Ductal Adenocarcinoma (PDAC)
Interventions
BMS-986523Drug
Specified dose on specified days
GemcitabineDrug
Specified dose on specified days
Nab-PaclitaxelDrug
Specified dose on specified days
CetuximabDrug
Specified dose on specified days
PembrolizumabDrug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse events (AEs)Time frame: Up to 3 years
- Number of participants with serious adverse events (SAEs)Time frame: Up to 3 years
- Number of participants with AEs meeting protocol-defined dose limiting toxicity (DLT) criteriaTime frame: Up to 3 years
- Number of participants with AEs leading to discontinuationTime frame: Up to 3 years
- Number of deathsTime frame: Up to 3 years
Locations
8 sites in 3 countries. Site status is shown where the registry gives one.
Johns Hopkins Hospital
Baltimore, Maryland · Recruiting
NEXT Oncology
San Antonio, Texas · Recruiting
START Mountain Region
West Valley City, Utah · Recruiting
NEXT Virginia
Fairfax, Virginia · Recruiting
BC Cancer Vancouver
Vancouver, British Columbia, Canada · Recruiting
Princess Margaret Cancer Centre
Toronto, Ontario, Canada · Recruiting
Local Institution - 0006
Badalona, Barcelona [Barcelona], Spain · Not yet recruiting
Local Institution - 0008
Hortaleza, Madrid, Spain · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.